Prader-Willi Syndrome Drug Pipeline — PatSnap Eureka
Prader-Willi Syndrome Drug Pipeline: Oxytocin, GLP-1 & Hypothalamic Pathway Approaches
The PWS therapeutic landscape is expanding beyond growth hormone replacement. Patent intelligence reveals seven distinct molecular strategies — from PC1 upregulation via cAMP signaling to GABA-A α3 modulation and KATP channel-based glycemic control — across seven active assignees.
Understanding the Molecular Architecture of PWS
Prader-Willi Syndrome is a rare, complex genetic neurobehavioral and metabolic disorder caused by loss of expression of paternally inherited imprinted genes on chromosome 15q11-q13, presenting canonically with hyperphagic obesity, central hypogonadism, and low growth hormone. Retrieved results consistently identify PWS as arising from a paternal deletion (~70% of cases), maternal uniparental disomy of chromosome 15 (~25%), or imprinting center defects in the 15q11-q13 region.
The SNORD116 non-coding snoRNA cluster — located within the minimum critical deletion region (~91 kb) — is central to PWS pathophysiology, with downstream effects on NHLH2 (a transcription factor) and PCSK1 (encoding prohormone convertase 1, PC1). PC1 is required for processing of hypothalamic neuropeptides including those in the oxytocin and POMC pathways. This mechanistic chain — SNORD116 → NHLH2 → PC1 → hypothalamic neuropeptide processing — is the most patent-dense target cluster in the retrieved dataset.
The PatSnap life sciences intelligence platform captures innovation signals across this expanding therapeutic landscape, including small-molecule, peptide, and receptor-targeted modalities addressing the POMC-MC4R axis, prohormone convertase 1, GABA-A receptor subtypes, GABAergic enzyme inhibition, and glycemic control in PWS.
Seven Distinct Drug Development Strategies in the PWS Pipeline
Patent intelligence from PatSnap Eureka reveals seven mechanistically distinct approaches to treating PWS, spanning hypothalamic neuropeptide restoration, receptor modulation, and metabolic comorbidity management.
PC1 Upregulation via cAMP Signaling
The most patent-dense single cluster in the dataset. Levo Therapeutics' multi-jurisdictional filing program describes upregulation of PC1 levels via PDE4 inhibitors and/or adenylate cyclase activators, which increase cAMP and thereby derepress NHLH2-dependent PC1 transcription in hypothalamic neurons. Evidence spans preclinical data in Snord116 paternal-deletion mouse models and human iPSC-derived neurons. The JP filing includes a clinical trial design schematic (Figure 8C), signaling IND-enabling progression.
WO · CA · AU · EP · MX · US · JP Preclinical → Early ClinicalMC4R Agonism (POMC-MC4R Pathway Restoration)
Two patent families from Rhythm Pharmaceuticals and Charité-Universitätsmedizin Berlin address MC4R agonists for PWS and hyperphagia. PWS-associated functional loss in the POMC-MC4R pathway — including reduced PCSK cleavage of POMC — leads to insufficient MSH and consequent hyperphagia. MC4R agonist peptides are described as administered at doses of 0.1–10 mg daily. Both filings identify PWS patients with POMC or PCSK mutations as candidate populations, representing a precision medicine framing characteristic of programs approaching clinical development.
CA · BR Preclinical → ClinicalGABA-A Receptor (α3 Subunit) Modulation
A substantial cluster of patents describes novel androsterone-based steroids — specifically 3α-ethyl-3β-hydroxy-5α-androstan-17-one and 3α-ethynyl-3β-hydroxy-5α-androstan-17-methoxime — as selective modulators of the α3 subtype of the GABA-A receptor. Retrieved patent texts explicitly list PWS, hyperphagia disorder, and hypothalamic obesity among therapeutic indications. Preclinical data cited in one filing (WO, 2023) reports >20% body weight reduction after 10 days of treatment in an animal model, with the text noting suitability for adolescents with PWS. A US filing with pending status (2025) signals continued active prosecution.
WO · CA · US (pending 2025) PreclinicalGABAergic Enzyme Inhibition (GABA-AT Inhibitor)
Ovid Therapeutics has filed patents in multiple jurisdictions describing (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid (KT-II-115 / CPP-115), an irreversible GABA aminotransferase inhibitor, for both seizure disorders and PWS. The therapeutic rationale encompasses improving one or more symptoms of PWS through modulation of GABAergic tone — relevant to both seizure control (a PWS comorbidity) and hypothalamic appetite circuit modulation. A separate Ovid filing addresses PDE10A inhibition for developmental syndromes broadly. The US filing is listed as inactive, which may indicate lapse or abandonment.
CA · MX · WO US Filing InactiveBicyclic Small Molecules
Neuren Pharmaceuticals has filed patents in BR, CO, and IL jurisdictions describing bicyclic compounds (Formulas I–IV or pharmaceutically acceptable salts, hydrates, stereoisomers, or prodrugs thereof) for PWS treatment. Three filings retrieved across 2023 IL and 2023 BR/CO jurisdictions indicate active international prosecution as recently as late 2023. Mechanistic detail is limited in retrieved records.
BR · CO · IL UndisclosedKATP Channel Openers for Glycemic Control
Soleno Therapeutics' 2025 WO patent describes co-administration of a KATP channel opener with a magnesium supplement for glycemic management in PWS patients, targeting the metabolic/diabetic comorbidity of PWS. The rationale centers on aberrant glycemic control accompanying PWS-associated obesity and insulin dysregulation. This represents a metabolic comorbidity approach rather than direct hyperphagia control — the most recently filed record in this dataset.
WO · 2025 UnspecifiedGLP-1 Receptor Agonism & Oxytocin
One patent retrieved addresses GLP-1R agonists for metabolic indications (VTV Therapeutics, CA, 2019) including obesity, but does not name PWS as a specific indication. The Ovid Therapeutics PWS patent text references oxytocin among "other treatments" for PWS alongside growth hormone, sex hormones, and behavioral therapy. Direct GLP-1 and oxytocin targeting patents for PWS were not retrieved as primary records in this dataset.
Adjacent / Referenced Not PrimaryPWS Pipeline at a Glance: Patent Density & Target Distribution
Visual summary of patent activity, therapeutic target coverage, and development stage signals derived from the retrieved PWS patent dataset via PatSnap Eureka.
Patent Family Count by Therapeutic Strategy
PC1/cAMP upregulation (Levo Therapeutics) is the most patent-dense PWS-specific strategy in the retrieved dataset, with 5+ family members across 6+ jurisdictions.
PWS Genetic Cause Distribution
Paternal deletion accounts for ~70% of PWS cases, maternal uniparental disomy for ~25%, and imprinting center defects for the remainder, according to retrieved patent records.
SNORD116 → NHLH2 → PC1 → Neuropeptide Processing: The Core PWS Mechanistic Cascade
Loss of SNORD116 expression downregulates NHLH2 transcription factor, reducing PC1/PCSK1 enzyme levels, impairing hypothalamic prohormone processing (oxytocin, POMC), and driving hyperphagia. PDE4 inhibitors and adenylate cyclase activators restore cAMP → NHLH2 → PC1 transcription.
Who Is Filing PWS Patents? A Biotech-Dominated Space
Innovation in PWS therapeutics in this dataset is predominantly patent-driven and concentrated among rare disease biotechs. No major pharmaceutical company is represented in PWS-specific retrieved records.
Monitor PWS Patent Prosecution in Real Time
PatSnap Eureka tracks filing status, lapse events, and new prosecution activity across all PWS-relevant assignees globally.
What the PWS Patent Landscape Signals for IP Strategy
Key strategic takeaways derived from patent record analysis via PatSnap analytics and the retrieved PWS dataset.
PC1/cAMP: The Most Defensible IP Position
PC1 upregulation via cAMP signaling represents the most patent-dense PWS-specific strategy in this dataset. Levo Therapeutics holds a broad multi-jurisdictional portfolio; competitors entering this space will need to design around PDE4 inhibition and adenylate cyclase activation claims as applied to PC1/NHLH2 in PWS.
MC4R Agonism: Precision Medicine Positioning
MC4R agonism positions Rhythm Pharmaceuticals at the intersection of genetically defined obesity and PWS, with a precision medicine framing that may support regulatory breakthrough or orphan drug designations. The Charité co-filing in Brazil signals international academic-industry collaboration in this space.
GABA-A α3: Differentiated CNS Mechanism with 2025 Activity
GABA-A α3 modulation by Umecrine AB represents a differentiated, CNS-targeted mechanism with recent US prosecution activity (2025), suggesting ongoing commercial development interest. The preclinical weight-loss data (>20% body weight reduction at 10 days) cited in retrieved filings, if reproducible in PWS-specific models, would represent a compelling clinical hypothesis.
Combination Approaches & Convergent Strategies in PWS Drug Development
Retrieved results signal several combination or convergent directions in the PWS pipeline. The Levo Therapeutics JP filing explicitly references oxytocin peptide form dysregulation in PWS/autism overlap, and PC1 is required for hypothalamic oxytocin prohormone processing. This suggests a mechanistic rationale — yet to be fully developed in retrieved filings — for combining PC1 upregulators with oxytocin-targeted agents.
Rhythm Pharmaceuticals records propose companion diagnostic-style patient selection (POMC/PCSK mutation status) prior to MC4R agonist treatment, representing a precision medicine approach for the POMC-deficient PWS subpopulation. This genotype-first framing aligns with FDA rare disease drug development frameworks for stratified patient populations.
The Umecrine AB filing scope explicitly includes PWS co-listed with polycystic ovarian syndrome, obesity, and diabetes, suggesting a single compound addressing both hyperphagic and metabolic dimensions of PWS. The Soleno Therapeutics 2025 WO filing describes a KATP opener + magnesium combination specifically for glycemic management in PWS — signaling emerging attention to metabolic comorbidities as an independent therapeutic target distinct from hyperphagia. For deeper competitive intelligence across these convergent strategies, PatSnap customers in rare disease use Eureka to track multi-target claim evolution in real time.
Signals suggest the field captured here is moving toward molecular stratification of PWS patients (by deletion type, POMC pathway mutation status) and multi-target approaches addressing both the hypothalamic appetite circuit and metabolic comorbidities simultaneously. The genetic complexity of PWS supports this multi-pathway therapeutic rationale.
Prader-Willi Syndrome Drug Pipeline — Key Questions Answered
PWS is a rare, complex genetic neurobehavioral and metabolic disorder caused by loss of expression of paternally inherited imprinted genes on chromosome 15q11-q13, presenting canonically with hyperphagic obesity, central hypogonadism, and low growth hormone. It arises from a paternal deletion (~70% of cases), maternal uniparental disomy of chromosome 15 (~25%), or imprinting center defects in the 15q11-q13 region.
PC1 (prohormone convertase 1, encoded by PCSK1) is downregulated in PWS iPSC-derived neurons and in hypothalami of fasted Snord116 paternal-deletion mice, implicating impaired processing of hypothalamic prohormones. SNORD116 downregulates NHLH2 (a transcription factor) which in turn reduces PC1 transcription, impairing processing of hypothalamic neuropeptides including those in the oxytocin and POMC pathways.
PWS-associated functional loss in the POMC-MC4R pathway — including reduced PCSK cleavage of POMC — leads to insufficient MSH (melanocyte-stimulating hormone) and consequent hyperphagia. MC4R agonist peptides bypass upstream POMC processing defects by directly activating MC4R with synthetic peptide agonists, administered at doses of 0.1–10 mg daily.
Umecrine AB describes novel androsterone-based steroids — specifically 3α-ethyl-3β-hydroxy-5α-androstan-17-one and 3α-ethynyl-3β-hydroxy-5α-androstan-17-methoxime — as selective modulators of the α3 subtype of the GABA-A receptor. Preclinical data cited in one filing (WO, 2023) reports >20% body weight reduction after 10 days of treatment in an animal model, with the text noting suitability for adolescents with PWS.
GLP-1R agonists are being investigated in PWS-related obesity in the broader field. One patent retrieved addresses GLP-1R agonists for metabolic indications including obesity, but does not name PWS as a specific indication. The Ovid Therapeutics PWS patent text references oxytocin among other treatments for PWS alongside growth hormone, sex hormones, and behavioral therapy.
In the retrieved dataset, Levo Therapeutics demonstrates the broadest geographic patent prosecution strategy with active filings across 6+ jurisdictions (WO, CA, AU, EP, MX, US, JP). Umecrine AB has the most recently prosecuted US filing (pending, December 2025 date). Other active assignees include Ovid Therapeutics, Rhythm Pharmaceuticals, Charité-Universitätsmedizin Berlin, Neuren Pharmaceuticals, and Soleno Therapeutics. No major pharmaceutical company is represented in PWS-specific records retrieved.
Still have questions about the PWS patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About PWSAccelerate Your PWS Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track rare disease patent pipelines, map molecular targets, and identify white space in emerging therapeutic areas.
References
- Methods of treating prader-willi syndrome — Levo Therapeutics, Inc., 2017, WO [Patent]
- Methods of treating prader-willi syndrome — Levo Therapeutics, Inc., 2017, CA [Patent]
- Methods of treating Prader-Willi syndrome — Levo Therapeutics, Inc., 2018, AU [Patent]
- Methods of treating prader-willi syndrome — Levo Therapeutics, Inc., 2019, EP [Patent]
- Methods of treating prader-willi syndrome — Levo Therapeutics, Inc., 2024, CA [Patent]
- How to Treat Prader-Willi Syndrome — Levo Therapeutics, Inc., 2019, JP [Patent]
- Methods of treating prader-willi syndrome — Levo Therapeutics, Inc., 2019, MX [Patent]
- Method of treating melanocortin-4 receptor pathway-associated disorders — Rhythm Pharmaceuticals, Inc., 2017, CA [Patent]
- Method of treatment of disorders associated with the melanocortin-4 receptor pathway — Charité-Universitätsmedizin Berlin, 2018, BR [Patent]
- 3α-substituted 3β-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the GABA-A receptor — Umecrine AB, 2023, WO [Patent]
- 3α-substituted 3β-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the GABA-A receptor — Umecrine AB, 2023, CA [Patent]
- Steroid as a modulator of GABA-A receptor — Umecrine AB, 2023, WO [Patent]
- 3β-hydroxy, 3α-ethyl steroids for modulation of the alpha-3 subtype of the GABA-A receptor — Umecrine AB, 2023, WO [Patent]
- 3-beta-hydroxy-3-alpha-ethyl steroids for modulation of the alpha-3 subtype of the GABA-A receptor — Umecrine Cognition AB, 2025, US [Patent]
- Methods of treating seizure disorders and prader-willi syndrome — Ovid Therapeutics Inc., 2018, CA [Patent]
- Methods of treating seizure disorders and prader-willi syndrome — Ovid Therapeutics Inc., 2019, MX [Patent]
- Methods of treating seizure disorders and prader-willi syndrome — Ovid Therapeutics Inc., 2020, US [Patent]
- Methods of treating developmental syndromes with PDE10A inhibitors — Ovid Therapeutics Inc., 2019, WO [Patent]
- Treatments of prader-willi syndrome — Neuren Pharmaceuticals Limited, 2023, IL [Patent]
- Treatments for Prader-Willi Syndrome — Neuren Pharmaceuticals Limited, 2023, BR [Patent]
- Treatments for Prader-Willi syndrome — Neuren Pharmaceuticals Limited, 2023, CO [Patent]
- Methods of managing glycemic control in prader-willi syndrome patients — Soleno Therapeutics, Inc., 2025, WO [Patent]
- Therapeutic uses of GLP-1r agonists — VTV Therapeutics LLC, 2019, CA [Patent]
- Prader-Willi Syndrome — GeneReviews, NCBI/NIH
- Prader-Willi Syndrome — National Human Genome Research Institute (NHGRI)
- Rare Disease Drug Development — U.S. Food and Drug Administration (FDA)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.